BioSpace News Archive

Press Release Solutions

Reach millions of readers
Share your story where it counts. BioSpace continues to grow year over year, with 1M monthly site visitors. Get your news in front of our growing audience of life science professionals.

January 31, 2025

Government

RFK Jr. Again Faces Scrutiny Over Vaccines on Day 2 of Confirmation Hearing

Senators on the Health, Education, Labor and Pensions committee were critical of Kennedy’s long history as an anti-vaccine campaigner.

January 31, 2025

·

2 min read

·

Tristan Manalac

A piggy bank crammed with $100 bills on a background of American cash

Venture capitalists

Blackstone Launches New $5B+ Fund for Life Sciences

Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of dollars into the industry.

January 31, 2025

·

2 min read

·

Tristan Manalac

Human hands symbolizing teamwork working on a pie chart with ai symbol in it. Arms point fingers hold pieces diagram chart. Distribute AI stock options on the market.

Earnings

AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical program to an adjunct approach—for now.

January 31, 2025

·

3 min read

·

Annalee Armstrong

External view of the U.S. Capitol building at sunset

IRA

Drug Pricing and the Uncertain Future of the IRA Under Trump

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug prices in the U.S., Trump has so far been mum on how the controversial law could evolve in the coming years.

January 31, 2025

·

4 min read

·

Jef Akst

Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.

Layoffs

ImmunityBio Continues Trimming Workforce While Working to Advance Anktiva

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

January 31, 2025

·

1 min read

·

Angela Gabriel

Novartis head office building in Dorval, Quebec, Canada

Earnings

Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

January 31, 2025

·

2 min read

·

Tristan Manalac

Approvals

Axsome’s Migraine Medicine Clears FDA Bar

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex’s non-opioid treatment Journavx.

January 31, 2025

·

2 min read

·

Tristan Manalac

Composite contemporary collage statue of justice themis femida on the background of the target as the concept and idea of justice and law. High quality photo

Editorial

You Can’t Buy Us: Biotechs Turn to Courts to Fight Off Potential Buyers

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO underscore the cutthroat nature of biopharma dealmaking.

January 31, 2025

·

3 min read

·

Annalee Armstrong

Illustration of a group of businessmen white-collar workers dismissed

Layoffs

Fractyl Goes All In on GLP-1 Off-Ramp Drug, Lays of 17% of Workforce

Fractyl Health is deprioritizing a type 2 diabetes trial in favor of a pivotal study of its endoscopy treatment Revita and parting with around 22 employees in an attempt to extend its runway into 2026.

January 31, 2025

·

1 min read

·

Dan Samorodnitsky